Trial Profile
A safety and efficacy study of canakinumab in Spanish patients with cryopyrin-associated periodic syndromes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2015
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2015 New trial record
- 05 Aug 2015 Results published in the Clinical and Experimental Rheumatology.